AssetMark Inc
PTCT icon

AssetMark Inc’s PTC Therapeutics PTCT Stock Holding History

AssetMark Inc’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$204 – 3638
2026
Q1 		$204 Buy
+3
New +$212 ﹤0.01% 3320
2021
Q2 		– Sell
-42
Closed -$2K – 1498
2021
Q1 		$2K Buy
42
+2
+5% +$119 ﹤0.01% 1197
2020
Q4 		$2K Hold
40
– – ﹤0.01% 1230
2020
Q3 		$2K Sell
40
-8
-17% -$394 ﹤0.01% 1142
2020
Q2 		$2K Buy
48
+16
+50% +$786 ﹤0.01% 1114
2020
Q1 		$1K Buy
+32
New +$1.61K ﹤0.01% 1288

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

AssetMark Inc's PTCT Position: Q2 2026 in Review

AssetMark Inc sold out of PTC Therapeutics (PTCT) in Q2 2026, closing a stake of 3 shares — an estimated $204 sold.

AssetMark Inc first reported a position in PTCT in Q1 2020 and held it in 6 quarters. The position peaked at $2K in Q1 2021. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • AssetMark Inc reported no remaining PTC Therapeutics position as of Q2 2026 after selling out during the quarter.
  • AssetMark Inc sold 3 PTC Therapeutics shares in Q2 2026, an estimated $204.
  • AssetMark Inc first reported a position in PTC Therapeutics in Q1 2020 and held it in 6 quarters.
  • AssetMark Inc's PTC Therapeutics position peaked at $2K in Q1 2021.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.